Cargando…

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Big and Intriguing Challenge Which May Be Resolved by Integrated Treatments Combining Locoregional and Systemic Therapies

SIMPLE SUMMARY: The purpose of this manuscript is to illustrate the difficulties associated with the treatment of the patient with recurrent metastatic SCCHN. This type of patient is very heterogeneous, including very different cases both as regards the natural history and the types of treatment to...

Descripción completa

Detalles Bibliográficos
Autores principales: Ionna, Franco, Bossi, Paolo, Guida, Agostino, Alberti, Andrea, Muto, Paolo, Salzano, Giovanni, Ottaiano, Alessandro, Maglitto, Fabio, Leopardo, Davide, De Felice, Marco, Longo, Francesco, Tafuto, Salvatore, Della Vittoria Scarpati, Giuseppina, Perri, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155962/
https://www.ncbi.nlm.nih.gov/pubmed/34069092
http://dx.doi.org/10.3390/cancers13102371
Descripción
Sumario:SIMPLE SUMMARY: The purpose of this manuscript is to illustrate the difficulties associated with the treatment of the patient with recurrent metastatic SCCHN. This type of patient is very heterogeneous, including very different cases both as regards the natural history and the types of treatment to be used. The authors then illustrated the possible therapeutic options available and tried to propose the best strategies to be adapted to the individual case, based on the characteristics of the patient and the disease. The main conclusion of the following work is that the multidisciplinary approach is the winning weapon in any patient. ABSTRACT: Squamous cell carcinoma of the head and neck (SCCHN) is a complex group of malignancies, posing several challenges to treating physicians. Most patients are diagnosed with a locally advanced disease and treated with strategies integrating surgery, chemotherapy, and radiotherapy. About 50% of these patients will experience a recurrence of disease. Recurrent/metastatic SCCHN have poor prognosis with a median survival of about 12 months despite treatments. In the last years, the strategy to manage recurrent/metastatic SCCHN has profoundly evolved. Salvage treatments (surgery or re-irradiation) are commonly employed in patients suffering from locoregional recurrences and their role has gained more and more importance in the last years. Re-irradiation, using some particularly fractionating schedules, has the dual task of reducing the tumor mass and eliciting an immune response against cancer (abscopal effect). In this review, we will analyze the main systemic and/or locoregional strategies aimed at facing the recurrent/metastatic disease, underlining the enormous importance of the multidisciplinary approach in these types of patients.